Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma
Authors' conclusion
Our real-world experience with L/P in metastatic BRAFWT-ATC demonstrates the clinical efficacy and safety of this combination, consistent with prior reports. A prospective clinical trial in the United States is ongoing (NCT#04171622).
Study context
- Population
- Patients with metastatic BRAF wild-type ATC treated with first-line L/P, January 2016–July 2024; median age 64 years (range, 41–84); all with distant metastases33 evaluable for response
- Participants
- 36 patients
- Outcome
- Confirmed ORR, PFS and OS
Methodological detailssingle-center, real-world
- Single-center
- Real-world
Main finding
As reported in the abstract
median follow-up 39.5 months (CI 8.1-54.3)
Confirmed overall response rate (ORR) (33/36 evaluable)
36%
Median progression-free survival (PFS)
6.2 months
CI 3.1–7.9
Median overall survival (OS)
7.7 months
CI 4.6–22.9
Observational data: associations, not effects.
Further findings
Median duration of response
- Median duration of response
- 16.0 months (CI 3.2-28.8)
Best overall response
- Confirmed complete response
- 3 (9%)
- Confirmed partial response
- 9 (28%)
- Stable disease
- 11 (33%)
- Progressive disease
- 10 (30%)
Safety
Treatment discontinuation for toxicity
- Stopped pembrolizumab due to immune-related toxicity
- 5 (14%)
- Pneumonitis
- 2
- Colitis
- 3
- Discontinued lenvatinib for concern of esophageal or tracheal fistula; no further intervention required
- 2
- Safety profile similar to previous studies
Original publication
Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma. Thyroid. Published 7 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →